MorphoSys AG — Regulatory Filings 2002

Aug 14, 2002

News Details

Ad-hoc | 14 August 2002 07:30

MorphoSys AG english

MorphoSys Announces First Milestone in Centocor Therapeutic Antibody Collaborati Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys Announces First Milestone in Centocor Therapeutic Antibody Collaborati MorphoSys AG (Neuer Markt: MOR), the Munich-based biotechnology company, today announced the achievement of a first milestone in its therapeutic antibody cooperation with Centocor, Inc. In achieving the milestone MorphoSys delivered several antibodies against an undisclosed target molecule provided by Centocor. The antibodies generated by MorphoSys were systematically optimized in order to meet nine different pre-defined success criteria. MorphoSys receives an undisclosed payment from Centocor for attaining the milestone. In December 2000, MorphoSys and Centocor, a subsidiary of Johnson & Johnson, signed a collaboration for the development of fully human antibodies in a wide range of therapeutic indications. The collaboration includes an option for the development of antibodies against up to 30 different target molecules from Centocor. The collaboration also grants Centocor the use of the MorphoSys HuCAL technology in its own research programs. In achieving the current milestone, MorphoSys delivered several antibodies against the target molecule from Centocor, fulfilling nine different pre-agreed success criteria. The antibodies were systematically engineered to meet all of the required attributes. end of ad-hoc-announcement (c)DGAP 14.08.2002 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 140730 Aug 02